Filgotinib maintained a favorable safety and efficacy profile for up to 8 years among patients with RA who participated in the DARWIN 3 LTE.

The U.S. Food and Drug Administration approved the expanded use of ARS Pharmaceuticals' nasal spray for severe allergic ...

AbbVie said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults ...

Find out more about how we test. We reviewed the Q Acoustics Concept 30 in April 2022, following their launch the previous October, and at the time of writing they are still available – and typically ...

A European Commission committee is recommending AbbVie's Rinvoq for treatment of giant cell arteritis following Phase 3 clinical trial results that showed efficacy and safety in the inflammatory ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AbbVie's upadacitinib (Rinvoq ... to receive a 7.5 mg or 15 mg dose of ...

In patients =65 years of age, there is an increased risk of adverse reactions with RINVOQ 30 mg once daily. Consequently, the recommended dose for long-term use in this patient population is 15 mg ...

The positive opinion is based on results from the pivotal Phase 3 SELECT-GCA trial that evaluated the efficacy and safety of upadacitinib ...

The positive opinion is based on results from the pivotal Phase 3 SELECT-GCA trial that evaluated the efficacy and safety of upadacitinib in adults with giant cell arteritis (GCA)1The primary ...